Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

James N. Kochenderfer, MD, Experimental Transplantation and Immunology Branch, National Cancer Institute in Bethesda, MD, discusses the B-cell antigen CD19 and its role in chemotherapy-resistant B-cell malignancies. At the 53rd Annual Meeting of the American Society of Hematology, held at the San Diego Convention Center, Kochenderfer presented data on 8 patients treated with an anti-CD19 chimeric antigen receptor. While the agent did cause some toxicity in patients, it was able to eliminate targeted cells.

>>>Return to the main conference coverage page.

Related Videos
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS